TP-317 for Treatment of Solid Tumors
TP-317 is being developed as adjunct to immune checkpoint inhibitors and chemotherapy for treatment of advanced solid tumors and as monotherapy for maintenance.
Unmet Need
Cancers evade immune surveillance and negate the benefit of immune checkpoint inhibitors (ICI) by suppressing the immune response in the tumor microenvironment, including abrogation of antigen presentation that is a pre-requisite for anti-tumoral immunity.
Our Solution
TP-317 counteracts immune evasion by steering phagocytosis (clearance) of tumor debris towards antigen presentation rather than immune tolerance. Based on this mechanism, TP-317 has prospects to improve efficacy when used in combination with standard-of-care therapies with no additional safety burden and as monotherapy for chronic maintenance.
Preclinical Evidence
TP-317 has shown single agent efficacy comparable to standard-of-care therapies in diverse tumor models. When combined with ICI or chemotherapy, TP-317 improves efficacy and in some cases can make non-responsive tumors responsive to ICI therapy. Data from RNA sequencing studies in B16F10 (melanoma) tumors have shown increased expression of MHC-I and MHC-II locus genes in TP-317 treated tumor tissue, suggesting that TP-317 is restoring antigen presentation machinery in the tumor microenvironment.